Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Koivunen, 2008, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res, 14, 4275, 10.1158/1078-0432.CCR-08-0168 Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025 Takeuchi, 2012, RET, ROS1 and ALK fusions in lung cancer, Nat Med, 18, 378, 10.1038/nm.2658 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X Lin, 2017, Targeting ALK: precision medicine takes on drug resistance, Cancer Discov, 7, 137, 10.1158/2159-8290.CD-16-1123 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107 Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov, 6, 1118, 10.1158/2159-8290.CD-16-0596 Johnson, 2014, J Med Chem, 57, 4720, 10.1021/jm500261q Shaw, 2017, Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncol, 18, 1590, 10.1016/S1470-2045(17)30680-0 Long, 2012, Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 1087, 10.1016/S1470-2045(12)70431-X Crino, 2016, Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 34, 2866, 10.1200/JCO.2015.65.5936 Kim, 2017, Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial, J Clin Oncol, 35, 2490, 10.1200/JCO.2016.71.5904 Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443 Novello, 2018, Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study, Ann Oncol, 29, 1409, 10.1093/annonc/mdy121 Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 18, 874, 10.1016/S1470-2045(17)30339-X Bylicki, 2017, Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer, Target Oncol, 12, 563, 10.1007/s11523-017-0510-9 Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101 Novello S, Mazieres J, Oh I, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). ESMO 2017 Congress; Madrid, Spain; Sept 11, 2017. Abstr 1299O_PR. Berger, 2013, CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives, Lung Cancer, 80, 242, 10.1016/j.lungcan.2013.02.004 Solomon, 2016, Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 34, 2858, 10.1200/JCO.2015.63.5888 Yoshida, 2016, Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer, Lung Cancer, 97, 43, 10.1016/j.lungcan.2016.04.006 Kim, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 17, 452, 10.1016/S1470-2045(15)00614-2